Bavarian Nordic's vaccine has potential to last longer than competition, says CEO

The world should be prepared for more Covid-19 jabs in the future, according to CEO of Bavarian Nordic Paul Chaplin, who highlights his company’s vaccine candidate as a bid for longer protection.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish biotech firm Bavarian Nordic’s CEO, Paul Chaplin, says that having a vaccine that provides longer protection against Covid-19 would be an advantage, as reported by Danish business daily Børsen.

Chaplin predicts a future with people receiving frequent Covid-19 shots. He hopes to beat both Pfizer and Moderna when it comes to vaccine longevity.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs